Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for most solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will ...

Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...

70 Bristol-Myers Squibb Co. (NYSE:BMY) is a global biopharmaceutical company focused on developing innovative medicines for serious diseases, particularly in oncology, cardiovascular conditions ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

Sanofi and Bristol-Myers Squibb have announced they are restructuring ... to offer the clinical benefits of these well-established products to millions of patients around the world.” ...

Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... However, competition in profitable areas like oncology and immunology is fierce, leading to price ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...